Eli Lilly's New Drug Mounjaro™ to Treat Type 2 Diabetes
Mounjaro™ (tirzepatide) injection, developed by Eli Lilly and Company, is a novel, dual-targeted therapy that has been demonstrated to enhance glycemic control in adult patients with type 2 diabetes.
In people with type 2 diabetes, a once-weekly glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptor agonist is recommended as a supplement to diet and exercise.
The single-molecule drug hasn't been tested in people who have had pancreatitis before, and it's not recommended for those who have type 1 diabetes.
The doses of Mounjaro are 2.5 mg, 5 mg, 7.5 mg, 10 mg, 12.5 mg, and 15 mg in an auto-injector pen with a concealed needle preattached.
The FDA's recent approval is based on outcomes from the Phase III SURPASS study, which included active comparators such as injectable 1mg semaglutide, insulin glargine, and insulin degludec.
The study looked at the efficacy of Mounjaro dosages of 5, 10, and 15 mg alone and in combination with diabetes medications such SGLT2 inhibitors, metformin, insulin glargine, and sulfonylureas.
The average A1C reduction was between 1.8 and 2.1 percent for 5mg Mounjaro and between 1.7 and 2.4 percent for both 10 and 15mg dosages of Mounjaro, according to trial data.
Although the medication is not intended for weight loss, mean change in body weight was a critical secondary outcome in all SURPASS trials.
The subjects that were given Mounjaro lost an average of 12 pounds (5 pounds) to 25 pounds (15 mg).
Nausea, diarrhea, decreased appetite, vomiting, constipation, indigestion, and stomach discomfort were all reported by at least 5% of those in the Mounjaro arm.
In addition, Mounjaro's labelling includes a boxed warning about thyroid C-cell tumours.
Type 2 diabetes is a chronic and progressive disease in which the body's blood sugar regulation is disrupted, resulting in an excess of sugar in the bloodstream. Circulatory, neurological, and immunological problems can be caused by high blood sugar levels.
Diabetes type 2 is the most common form of diabetes. It takes time to develop, and those with it can suffer for years without experiencing any symptoms. Increased thirst and hunger, frequent infection and urine, unintentional weight loss, hazy vision, weariness, slow-healing wounds, and numbness or tingling feelings in the hands and feet are all signs and symptoms of the condition.
